LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model

No treatments exist to slow or halt Parkinson’s disease (PD) progression; however, inhibition of leucine-rich repeat kinase 2 (LRRK2) activity represents one of the most promising therapeutic strategies. Genetic ablation and pharmacological LRRK2 inhibition have demonstrated promise in blocking α-sy...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Mol Ther Nucleic Acids
Main Authors: Zhao, Hien Tran, John, Neena, Delic, Vedad, Ikeda-Lee, Karli, Kim, Aneeza, Weihofen, Andreas, Swayze, Eric E., Kordasiewicz, Holly B., West, Andrew B., Volpicelli-Daley, Laura A.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Gene & Cell Therapy 2017
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5573879/
https://ncbi.nlm.nih.gov/pubmed/28918051
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omtn.2017.08.002
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki